Comparison
GHK-Cu vs. Semaglutid
Two peptides side-by-side — identity, evidence base, legal status and known adverse events.
Identity
Category
Cosmetic
Metabolic
CAS no.
49557-75-7
910463-68-2
Molecular weight
340.4 g/mol
4113.6 g/mol
Half-life
no data
165 h
Sequence
GHKmodifiziertes GLP-1-Analogon (31 AS) mit C18-Fettsäure-LinkerMechanism of action
GHK-Cu
Endogenous tripeptide (glycyl-L-histidyl-L-lysine) that chelates copper(II) ions. In skin-cell models and skin biopsies an influence on collagen synthesis, antioxidant markers, gene-expression profiles and wound-healing processes has been described. In topical use in cosmetic studies, changes in various skin parameters have been reported.
Semaglutid
Long-acting agonist at the GLP-1 receptor. Structurally a modified glucagon-like peptide 1 whose long half-life is achieved via a fatty-acid side chain and reversible albumin binding. Acts centrally on satiety and peripherally on glucose-dependent insulin secretion and delayed gastric emptying.
Evidence base
Highest evidence
Human trial
Human RCT
Studies
3
4
of which in humans
1
3
Effects recorded
4
3
Open conflicts
1
1
Documented adverse events
2
5